Mercader M, Swift L, Sood S, Asfour H, Kay M, Sarvazyan N. Use of endogenous NADH fluorescence for real-time in situ visualization of epicardial radiofrequency ablation lesions and gaps. Am J Physiol Heart Circ Physiol 302: H2131-H2138, 2012. First published March 9, 2012; doi:10.1152/ajpheart.01141.2011.-Radiofrequency ablation (RFA) aims to produce lesions that interrupt reentrant circuits or block the spread of electrical activation from sites of abnormal activity. Today, there are limited means for real-time visualization of cardiac muscle tissue injury during RFA procedures. We hypothesized that the fluorescence of endogenous NADH could be used as a marker of cardiac muscle injury during epicardial RFA procedures. Studies were conducted in blood-free and blood-perfused hearts from healthy adult Sprague-Dawley rats and New Zealand rabbits. Radiofrequency was applied to the epicardial surface of the heart using a 4-mm standard blazer ablation catheter. A dual camera optical mapping system was used to monitor NADH fluorescence upon ultraviolet illumination of the epicardial surface and to record optical action potentials using the voltage-sensitive probe RH237. Epicardial lesions were seen as areas of low NADH fluorescence. The lesions appeared immediately after ablation and remained stable for several hours. Real-time monitoring of NADH fluorescence allowed visualization of viable tissue between the RFA lesions. Dual recordings of NADH and epicardial electrical activity linked the gaps between lesions to postablation reentries. We found that the fluorescence of endogenous NADH aids the visualization of injured epicardial tissue caused by RFA. This was true for both blood-free and blood-perfused preparations. Gaps between NADH-negative regions revealed unablated tissue, which may promote postablation reentry or provide pathways for the conduction of abnormal electrical activity. catheter ablation; arrhythmias; lesion; imaging; atrial fibrillation RADIOFREQUENCY ABLATION (RFA) is an effective therapy for treating atrial and ventricular rhythm disturbances (16). Nearly 100,000 RFA procedures are performed annually in the United States to treat cardiac arrhythmias (29). RFA targets the key elements of reentrant pathways and/or abnormal ectopic loci without damaging a significant amount of adjacent healthy myocardium and coronary vessels.RFA lesion size is not simply a function of delivered energy but depends on many factors, including the contact between the catheter tip and the tissue, the thickness of the myocardium, the amount of blood flow, and the presence of fat (16,33). Conventional electroanatomical mapping systems map mainly the location of the catheter tip but not the extent of tissue injury caused by ablation. Therefore, as of today, RFA ablation lesions are created with minimal information regarding the physiological condition of the affected tissue.Gaps of excitable tissue between ablation lesions are directly related to arrhythmia recurrences. Two main strategies have been proposed to reduce the inc...